Nova Arc
Nova Arc provides at-home ovarian health blood tests that measure biomarkers to assess egg quality, perimenopause status, and ovarian age. The service includes two cycle-timed tests per year, clinician-reviewed reports delivered in about two days, and personalized daily protocols based on individual results. Tests are analyzed at Quest or Labcorp and read against proteins found in real human ovarian tissue.
- Healthcare Technology
- Digital Health
- Data & Analytics
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Ovarian health, perimenopause, and fertility planning are poorly understood and underserved areas of women's healthcare, leaving many individuals without clear guidance on how their reproductive biology changes over time. Standard medical care often treats these as isolated events rather than a continuous trajectory, making it difficult for people to anticipate symptoms, plan for fertility windows, or prepare for hormonal transitions. Most women are unaware of the significant health risks—including heart disease, dementia, and bone loss—that are linked to ovarian aging.
Solution
Nova Arc provides an at-home ovarian health test that measures biomarkers from a small blood sample to assess ovarian age, egg quality estimates, and perimenopause status. The platform delivers personalized results in plain language within about two days, reviewed by a clinician, along with a custom protocol covering nutrition, lifestyle, and medical follow-up recommendations. Members receive daily updates based on their ovarian biology and retest after six months to track changes over time. The service combines blood data with wearable and symptom context to create a comprehensive view of reproductive health and its connections to overall aging, heart health, metabolism, and cognitive function. Each test is read against proteins found in real human ovarian tissue, anchoring the reading in the organ rather than inferring from symptoms alone.
Target Audience
Primary users are women approaching or experiencing perimenopause, those actively planning fertility or considering egg freezing, and individuals managing ovarian health concerns such as polycystic ovary syndrome or endometriosis who want a data-driven approach to their reproductive health.
Features
- Two-minute at-home blood test using a sterile, single-use Tasso device, or optional in-lab draw, with samples analyzed at Quest or Labcorp via Fullscript
- Ovarian age assessment compared against the user's own baseline, not population averages
- Estimated egg quality and suggested window for egg freezing based on individual biomarker levels
- Perimenopause staging with early-warning detection and hormone recommendations when appropriate
- Clinician-reviewed results with connection to a physician for medical decisions
- Integration of wearable and symptom data alongside blood biomarkers for a fuller health picture
- Cycle-timed testing protocol with two tests per year, 6 months apart, to track progression and response to interventions
- Custom daily protocols covering diet, supplements, and lifestyle adjustments tailored to individual ovarian results
- HSA/FSA eligibility through Truemed with a Letter of Medical Necessity for qualified customers
- HIPAA-compliant, CLIA-certified, and CAP-accredited testing infrastructure